Udo Dunzendorfer

Sildenafil - Milestones in Drug Therapy Udo Dunzendorfer Softcover reprint of the original 1st ed. 2004 edition

Description for Sales People: Sildenafil, for the treatment of erectile dysfunction, is one of the first products that has made its way successfully from basic NO (nitrous oxide) research, to clinical routine therapy. Sildenafil, part of the Milestones in Drug Therapy series, presents the major breakthroughs in the field of NO physiology and pharmacology that led to the development of the drug, as well as clinical applications in a one-source guide. Table of Contents: From the contents: The detection and developement of sildenafil.- Sildenafil, pharmacology of a highly selective PDE-5 inhibitor.- Sildenafil, gold-standard in the treatment of erectile dysfunction.- Sildenafil in the prevention and treatment of erectile dysfunction after prostate cancer treatment.- ED-treatment with sildenafil improves quality of life and partnership.- Sildenafil in ED Therapy in patients under psychopharmacological drugs.- Cardiovasculare safety of sildenafil in the treatment of erectile dysfunction.- Sildenafil in female sexual dysfunction.- Penis pathology, as mixed urolgical ED under NO managing drugs, the mono and multiple therapy approach.- Cardiovascular events under Sildenafil and other NO managing drugs.- Sildenafil in pulmonary hypertension.- Sildenafil improves endothelial dysfunction.- Sildenafil in rehabiltative procedures of neurologically disease patients.- The PILRS-Study: The PDE V Inhibitor low response study in patients with ED.- The cultural impact of SildenafilPublisher Marketing: This drug is a landmark discovery, which consequently has become the definitive therapy for the treatment of erectile dysfunction (ED). Following the major breakthrough in the field of nitric oxide (NO)-physiology and pharmacology leading to sildenafil being marketed, the most current information is presented in this reference book, including ongoing research from several disparate groups about NO as endothelium-derived relaxing factor (EDRF) and also as a neurotransmitter for nerves innervating erectile tissue in mammals. The development of sildenafil as an oral phosphodiesterase-5 (PDE5) inhibitor drug for the treatment of ED resulted in one of the first products, which made its way successfully from basic NO research to routine clinical therapy. This volume addresses all fields of sildenafil application in both men and women. In a highly competitive research environment with a critical medical need for drug improvements the reader will learn more about clinical resistance to sildenafil treatment and the modalities to overcome the failure rates. The individual chapters cover clinical use, pharmacokinetics, pharmacodynamics, biochemistry, and cultural aspects. They are written by leading experts in their respective fields. Therefore, readers whether professionals in the pharmaceutical industry, physicians treating ED, biochemists, chemists or pharmacologists will find a detailed and up-to-date knowledge base about current research activities and an excellent overview for further research on this compound class and its cultural impact."